Related references
Note: Only part of the references are listed.Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Jing He et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone
Luz P. Blanco et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Update on Lupus Nephritis: Core Curriculum 2020
Samir Parikh et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus
Elena Elefante et al.
RMD OPEN (2020)
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
Sudha Visvanathan et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
Rita Kansal et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
Y. K. Onno Teng et al.
BMJ OPEN (2019)
Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus
Per Eriksson et al.
FRONTIERS IN PHARMACOLOGY (2019)
Efficacy and Safety of Vitamin D Supplementation in Patients With Systemic Lupus Erythematosus: A Meta-analysis of Randomized Controlled Trials
Ronghao Zheng et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2019)
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies
Andreas Schwarting et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Altered recruitment of Lyn, Syk and ZAP-70 into lipid rafts of activated B cells in Systemic Lupus Erythematosus
Ana Vasquez et al.
CELLULAR SIGNALLING (2019)
The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts
M. Frodlund et al.
LUPUS (2019)
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Martin Aringer et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A systematic review and meta-analysis
Dorian Parisis et al.
AUTOIMMUNITY REVIEWS (2019)
Association between circulating 25-hydroxyvitamin D and systemic lupus erythematosus: A systematic review and meta-analysis
Shi-Yang Guan et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)
CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies
Hong Qin et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
Alessia Alunno et al.
CELLS (2019)
Mechanisms of action and historical facts on the use of intravenous immunoglobulins in systemic lupus erythematosus
Tatiana Martinez et al.
AUTOIMMUNITY REVIEWS (2019)
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis
Brad H. Rovin et al.
KIDNEY INTERNATIONAL (2019)
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
Alexis Jones et al.
BMJ OPEN (2019)
Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men
A. Schwarting et al.
LUPUS (2018)
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
Eoghan M. McCarthy et al.
RHEUMATOLOGY (2018)
CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Miliotou N. Androulla et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2018)
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study
Luca Iaccarino et al.
JOURNAL OF AUTOIMMUNITY (2018)
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
Zhi-Wei Lai et al.
LANCET (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus
Tomonori Ishii et al.
MODERN RHEUMATOLOGY (2018)
Physical activity and sedentary behavior in patients with Systemic Lupus Erythematosus
Domenico Paolo Emanuele Margiotta et al.
PLOS ONE (2018)
Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review
Domenico Paolo Emanuele Margiotta et al.
BMC NEPHROLOGY (2018)
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study
Joan T. Merrill et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Joan T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Role of Human Leukocyte Antigens (HLA) in Autoimmune Diseases
Gergely Bodis et al.
RHEUMATOLOGY AND THERAPY (2018)
Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort
Chiara Tani et al.
LUPUS SCIENCE & MEDICINE (2018)
Remission in systemic lupus erythematosus: durable remission is rare
Theresa R. Wilhelm et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Hydroxychloroquine in systemic lupus erythematosus (SLE)
C. Ponticelli et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
Venkat Reddy et al.
RHEUMATOLOGY (2017)
New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab
Chrysanthi Staveri et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study
Sophie Grabar et al.
VACCINE (2017)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
Megan E. B. Clowse et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
William Stohl et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Treat to target, remission and low disease activity in SLE
Eric F. Morand et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2017)
Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study
Vera Golder et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J. T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Kate Franklyn et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)
Kenneth C. Kalunian et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D. A. Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review
Andreas Kronbichler et al.
AUTOIMMUNITY REVIEWS (2016)
First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study
Andreas Schwarting et al.
RHEUMATOLOGY AND THERAPY (2016)
Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial
Zhihong Liu et al.
ANNALS OF INTERNAL MEDICINE (2015)
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Tobias Alexander et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Epigenetic Aspects of Systemic Lupus Erythematosus
Manfred Relle et al.
RHEUMATOLOGY AND THERAPY (2015)
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
David Klatzmann et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
Vibeke Strand et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Systemic lupus erythematosus: a therapeutic challenge for the XXI century
Manuel F. Ugarte-Gil et al.
CLINICAL RHEUMATOLOGY (2014)
Intravenous Immunoglobulin in the Therapeutic Armamentarium of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Rajalingham Sakthiswary et al.
MEDICINE (2014)
Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity
C. Sjowall et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2014)
Efficacy and Safety of Abatacept in Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
M. A. Dooley et al.
LUPUS (2013)
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)
M. Witt et al.
LUPUS (2013)
Oxidative stress in the pathology and treatment of systemic lupus erythematosus
Andras Perl
NATURE REVIEWS RHEUMATOLOGY (2013)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
N-Acetylcysteine Reduces Disease Activity by Blocking Mammalian Target of Rapamycin in T Cells From Systemic Lupus Erythematosus Patients A Randomized, Double-Blind, Placebo-Controlled Trial
Zhi-Wei Lai et al.
ARTHRITIS AND RHEUMATISM (2012)
BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus
Fabien B. Vincent et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity
Georg H. Stummvoll et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Network Analysis of Associations Between Serum Interferon-α Activity, Autoantibodies, and Clinical Features in Systemic Lupus Erythematosus
Corinna E. Weckerle et al.
ARTHRITIS AND RHEUMATISM (2011)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
MECHANISMS OF DISEASE Systemic Lupus Erythematosus
George C. Tsokos
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Efficacy and Safety of Abatacept in Patients With Non-Life-Threatening Manifestations of Systemic Lupus Erythematosus Results of a Twelve-Month, Multicenter, Exploratory, Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial
J. T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Prolonged Effects of Short-Term Anti-CD20 B Cell Depletion Therapy in Murine Systemic Lupus Erythematosus
Kai W. Bekar et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Prednisone, Lupus Activity, and Permanent Organ Damage
Mae Thamer et al.
JOURNAL OF RHEUMATOLOGY (2009)
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus:: Data from LUMINA, a multiethnic US cohort (LUMINA L)
Graciela S. Alarcon et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus
Elizabeth C. Jury et al.
JOURNAL OF IMMUNOLOGY (2006)
IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria:: a long term observational study
GH Stummvoll et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus
AT Borchers et al.
AUTOIMMUNITY REVIEWS (2004)
Immunosuppressive therapy in lupus nephritis -: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
FA Houssiau et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
